Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,882 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Myeloma clinical outcomes following the first wave of COVID-19: results from the Thames Valley Cancer Alliance (UK).
Sharpley FA, Larham J, Haines A, Djebbari F, Tseu B, Leary H, Vallance G, Panitsas F, Ferguson L, Roberts P, Peniket A, Gooding S, Kothari J, Moore S, Ramasamy K. Sharpley FA, et al. Among authors: moore s. Br J Haematol. 2021 Mar;192(6):e136-e139. doi: 10.1111/bjh.17261. Epub 2020 Dec 16. Br J Haematol. 2021. PMID: 33326594 Free article. No abstract available.
A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1.
Chavda SJ, Maciocia PM, Mesiri P, Counsell N, Kothari J, Bird A, Mariner C, Chew A, Clesham K, Moore S, Percy L, Rismani A, D'Sa S, Rabin N, Popat R, Yong K. Chavda SJ, et al. Among authors: moore s. Br J Haematol. 2019 Apr;185(2):350-353. doi: 10.1111/bjh.15487. Epub 2018 Jul 9. Br J Haematol. 2019. PMID: 29984833 Free article. No abstract available.
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
Cohen OC, Counsell N, Rabin N, Popat R, Owen RG, Popova B, Schofield O, Clifton-Hadley L, Lyons-Lewis J, Rawstron A, Spence C, de Tute RM, Hughes D, Moore S, Smith P, Yong KL. Cohen OC, et al. Among authors: moore s. Br J Haematol. 2019 Jun;185(5):948-951. doi: 10.1111/bjh.15649. Epub 2018 Nov 20. Br J Haematol. 2019. PMID: 30460696 Free article. No abstract available.
Clinical outcomes of bortezomib-based therapy in myeloma.
Djebbari F, Srinivasan A, Vallance G, Moore S, Kothari J, Ramasamy K. Djebbari F, et al. Among authors: moore s. PLoS One. 2018 Dec 12;13(12):e0208920. doi: 10.1371/journal.pone.0208920. eCollection 2018. PLoS One. 2018. PMID: 30540831 Free PMC article.
Carfilzomib therapy for relapsed myeloma: results of a UK multicentre experience.
Djebbari F, Hubenov H, Neelakantan P, Wolf J, Offer M, Khera A, Louka E, Vallance G, Kothari J, Moore S, Ramasamy K. Djebbari F, et al. Among authors: moore s. Br J Haematol. 2020 Feb;188(4):e57-e60. doi: 10.1111/bjh.16324. Epub 2019 Dec 2. Br J Haematol. 2020. PMID: 31792927 Free article. Clinical Trial. No abstract available.
Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care.
Djebbari F, Panitsas F, Eyre TA, Prodger C, Davies F, Burton K, Khera A, Vallance G, Moore S, Kothari J, Peniket A, Ramasamy K. Djebbari F, et al. Among authors: moore s. Haematologica. 2020 Sep 1;105(9):e474-479. doi: 10.3324/haematol.2019.240762. Haematologica. 2020. PMID: 33054067 Free PMC article. No abstract available.
Efficacy and tolerability of VCD chemotherapy in a UK real-world dataset of elderly transplant-ineligible newly diagnosed myeloma patients.
Rampotas A, Djebbari F, Panitsas F, Lees C, Tsagkaraki I, Gomes AR, Prideaux S, Chen L, Prodger C, Khera A, Gray N, Ellis L, Sangha G, Lim WY, Eyre TA, Moore S, Ramasamy K, Kothari J. Rampotas A, et al. Among authors: moore s. Eur J Haematol. 2021 Apr;106(4):563-573. doi: 10.1111/ejh.13588. Epub 2021 Feb 5. Eur J Haematol. 2021. PMID: 33496996
5,882 results